James W. Black, a Scottish pharmacologist whose discovery of beta blockers and another class of drugs extended the lives of millions of people with heart and stomach disorders and earned him a Nobel Prize in 1988, died on March 21. He was 85.

The University of Dundee in Scotland, where Dr. Black was chancellor from 1992 to 2006, confirmed his death without giving the cause or saying where he died.

In the mid-1960s, Dr. Black, leading a team of researchers, developed the first beta-blocker drug, propanolol, which was marketed as Inderal. He subsequently developed, in the 1970s, an anti-ulcer drug, cimetidine, marketed as Tagamet.

The discoveries are considered among the most important medical advances in the 20th century, and the drugs have been among the most prescribed in the world.

Advertise with us

The arrival of propranolol and similar drugs ultimately changed the practice of cardiology. Dr. Black's initial aim was to relieve the pains of angina pectoris, a painful heart condition for which nitrate drugs, like nitroglycerine, were virtually all that doctors could prescribe.

But doctors soon found that beta blockers could be useful for treating heart attacks and heart rhythm abnormalities and lowering high blood pressure. Not only did the drugs help relieve angina pain, they also lowered death rates. Moreover, beta blockers are sometimes used to treat migraine headaches and anxiety, among other conditions.

Dr. Black started out working in academia. But in 1958 he went against the academic grain by moving to a drug company.

Circumstances had left him little choice. In 1958, Dr. Black sought a grant from Imperial Chemical Industries to pursue his goal of developing a beta blocker. The company said it would be easier if he worked with others at its new campus instead of his laboratory at the University of Glasgow. Dr. Black agreed and went on to become one of the rare scientists to receive a Nobel Prize for work performed in industry. The two scientists with whom he shared the prize, Gertrude B. Elion and George H. Hitchings, who discovered different drugs, also worked for industry.

In the research that led to propanolol, Dr. Black picked up on a theory that had been developed by Raymond Ahlquist and that others had ignored for years. Ahlquist, who died in 1983, proposed that there were two different receptors, alpha and beta, and that they caused different responses in heart muscle.

Advertise with us

Dr. Black focused on the beta receptors, the sites on heart muscle cells to which the stress hormones adrenaline and noradrenaline bind to make the heart work harder. Blocking the beta receptor would have a calming effect, Dr. Black reasoned.

At the same time he sought a drug to relieve the pain of angina, which results from oxygen deprivation in the heart. Other research was aimed at increasing the flow of oxygen-rich blood to the heart. Dr. Black's alternative strategy was to create a drug that would decrease the heart's requirement for oxygen. The Nobel committee said he was the first scientist to recognize such an alternative therapeutic strategy for angina.

The committee also cited him for developing drugs through a rational process based on the understanding of basic biochemical and physiological processes, rather than through the way most drugs were developed -- through happenstance or the chemical modification of natural products.

In a lecture in accepting the prize, in Stockholm, Dr. Black said he had to start cold in his quest because no compounds known at that time could diminish adrenalin's actions on the heart.

In 1962, Dr. Black's team created one agent, pronethalol, which confirmed Ahlquist's concept but which could not be marketed because of its toxic effects. Dr. Black went on to create propanolol in 1964. It was not approved for use in the United States until 1973.

Advertise with us

From 1964 to 1973, Dr. Black was head of biological research at Smith, Kline and French. There he also investigated the effects of a natural substance found in the body, histamine, which, among other things, stimulates the secretion of acid in the stomach, a factor in ulcers. At the time, histamine's effects could be only partly blocked by antihistamines and none of the drugs then available could block histamine's role in acid production.

In this research, Dr. Black applied the same method he used in beta-blocker experiments. This time the target was the H-2 receptor. He came up with cimetidine, or Tagamet.